Expertise in
7
conditions

Dr. Julio Rosenstock

Endocrinology
Dallas Diabetes And Endocrine Center
7777 Forest Ln Ste C685, 
Dallas, TX 
Expertise in
7
conditions
Dallas Diabetes And Endocrine Center
7777 Forest Ln Ste C685, 
Dallas, TX 

Overview

Julio Rosenstock is an Endocrinologist practicing medicine in Dallas, Texas.

Dr. Rosenstock is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Maturity Onset Diabetes of the Young, Type 2 Diabetes (T2D), Low Blood Sugar, and Type 1 Diabetes (T1D).

He is actively involved in clinical research, co-authoring 327 peer reviewed articles and participating in 26 clinical trials.

Specialties

Endocrinology

Licenses

Internal Medicine in TX

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Dallas Diabetes and Endocrine Center
7777 Forest Ln Ste C685, Dallas, TX 75230

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

24 Clinical Trials

A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes
A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes
Enrollment Status: Active_not_recruiting
Publish Date: December 12, 2025
Intervention Type: Drug
Study Phase: Phase 4
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
Enrollment Status: Active_not_recruiting
Publish Date: November 19, 2025
Intervention Type: Drug
Study Drug: HM15211
Study Phase: Phase 2
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Completed
Publish Date: August 24, 2025
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Enrollment Status: Completed
Publish Date: July 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes
A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 2
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)
Enrollment Status: Completed
Publish Date: May 22, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Enrollment Status: Completed
Publish Date: May 16, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
Enrollment Status: Completed
Publish Date: April 08, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)
A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)
Enrollment Status: Completed
Publish Date: November 02, 2023
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Lispro, Insulin Glargine
Study Phase: Phase 3
View 9 Less Clinical Trials

272 Total Publications

Sexual Dimorphism and Age Effects in CKD and Type 2 Diabetes in the CONFIDENCE Trial.
Sexual Dimorphism and Age Effects in CKD and Type 2 Diabetes in the CONFIDENCE Trial.
Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: March 27, 2026
Similar Doctors
Expertise in
14
conditions
Dr. Abhimanyu Garg
Endocrinology
Expertise in
14
conditions
Dr. Abhimanyu Garg
Endocrinology

University Of Texas Southwestern Medical Center

5323 Harry Hines Blvd, 
Dallas, TX 
 (7.9 miles away)
214-645-2800
Languages Spoken:
English
See accepted insurances

Abhimanyu Garg is an Endocrinologist practicing medicine in Dallas, Texas. Dr. Garg is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Acrorenal Mandibular Syndrome, Familial Partial Lipodystrophy, Congenital Generalized Lipodystrophy, Familial Hypertriglyceridemia, and Gastric Bypass.

Expertise in
29
conditions
Dr. Naim Maalouf
Endocrinology
Expertise in
29
conditions
Dr. Naim Maalouf
Endocrinology

University Of Texas Southwestern Medical Center

5323 Harry Hines Blvd, 
Dallas, TX 
 (7.9 miles away)
214-645-2870
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Naim Maalouf is an Endocrinologist practicing medicine in Dallas, Texas. Dr. Maalouf is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Milk-Alkali Syndrome, Hypercalcemia, Hyperparathyroidism, Parathyroidectomy, and Ureteroscopy.

Expertise in
10
conditions
Dr. Ildiko Lingvay
Endocrinology
Expertise in
10
conditions
Dr. Ildiko Lingvay
Endocrinology

University Of Texas Southwestern Medical Center

5323 Harry Hines Blvd, 
Dallas, TX 
 (7.9 miles away)
214-645-2868
Languages Spoken:
English
See accepted insurances

Ildiko Lingvay is an Endocrinologist practicing medicine in Dallas, Texas. Dr. Lingvay is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Type 2 Diabetes (T2D), Low Blood Sugar, Maturity Onset Diabetes of the Young, Obesity, and Gastric Bypass.

Frequently Asked Questions about Dr. Julio Rosenstock

How do I make an appointment with Dr. Julio Rosenstock?

You can book an appointment with Dr. Julio Rosenstock by calling their office at 972-566-7799. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Julio Rosenstock a top-rated expert for Maturity Onset Diabetes of the Young?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Julio Rosenstock is classified as an Elite expert for Maturity Onset Diabetes of the Young, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Julio Rosenstock specialize in?

While Dr. Julio Rosenstock is a Endocrinology, they have specific expertise in Maturity Onset Diabetes of the Young, Type 2 Diabetes (T2D), and Low Blood Sugar. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Endocrinology.

Does Dr. Julio Rosenstock participate in research or clinical trials?

Yes. Dr. Julio Rosenstock has published 272 articles and abstracts on conditions like Maturity Onset Diabetes of the Young. You can view a list of Dr. Julio Rosenstock's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Julio Rosenstock accept my insurance?

Dr. Julio Rosenstock accepts most major insurance plans, including Aetna and Baylor Scott & White Health. We recommend calling the office directly at 972-566-7799 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rosenstock's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile